Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
The occurrence of macular edema as an adverse effect of fingolimod is well documented. Treatment modalities used to manage fingolimod-associated macular edema (FAME) have included nonsteroidal anti-inflammatory agents and sub-tenon injection. We describe two cases where intravitreal injection is used to successfully treat FAME in patients who were previously unsuccessfully treated with topical nonsteroidal anti-inflammatories.
Department of Ophthalmology and the Division of Medicine, Flinders University, Australia.
Sophie
S
Thoo
Department of Ophthalmology and the Division of Medicine, Flinders University, Australia.
Sudha
S
Cugati
Flinders Medical Centre and Flinders University, Australia.
Andrew
A
Lee
Department of Ophthalmology, Flinders Medical Centre and Flinders University, Flinders Drive, Bedford Park, SA 5042 Australia Celia.Chen@health.sa.gov.au.
Celia
C
Chen
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008269:Macular Edema / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D014221:Triamcinolone / Q000008:administration & dosage / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D014221:Triamcinolone; D000068876:Fingolimod Hydrochloride
Fingolimod; edema; multiple sclerosis; steroid